| Name | MK-0557 |
| Description | MK-0557 is a selective and orally available antagonist of the neuropeptide Y5 receptor (Ki: 1.6 nM). |
| In vitro | MK-0557 has a Ki=1.3 nM at the human NPY5R, with similar affinities at rhesus, mouse, and rat NPY5R. MK-0557 has no significant binding to the human NPY1R, NPY2R, NPY4R, or mouse NPY6R at concentrations of 10 μM [2]. |
| In vivo | MK-0557 counteracts the NPY5R-selective agonist's influence on body-weight gain and hyperphagia in C57BL/6J mice, also markedly reducing body-weight gain in diet-induced obese (DIO) mice. A 40% reduction in body-weight gain is achieved by day 35 in lean mice shifted from regular chow to a medium high-fat diet (4.2 kcal/g), following treatment with MK-0557 at a dosage of 30 mg/kg PO QD[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 25 mg/mL (61.52 mM)
|
| Keywords | MK0557 | Neuropeptide Y Receptor | MK 0557 | inhibit | Inhibitor | NPY receptor | MK-0557 |
| Inhibitors Related | AC-263093 | HT-2157 | Galanin (1-16), mouse, porcine, rat | L 152804 | GW438014A | Peptide YY (PYY) (3-36), human | Selvigaltin | SF-22 | JNJ-31020028 | DF-1012 FA | AR-M 1896 Acetate | AC-099 hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Obesity Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
